Nutriop

Longevity investment: small sums behind big ideas

Latest articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...
Nutriop

Sonia Arrison talks about her journey to becoming an early stage investor and what longevity means to her.

While longevity is now seeing increasing interest from major Silicon Valley investment firms, companies in our sector still depend heavily on smaller investment firms and individuals, especially in their early stages. Despite investing relatively small amounts, the contributions from firms like 100 Plus Capital are no less vital to the continued growth of the longevity ecosystem than that of the bigger players.

Longevity.Technology: Sonia Arrison knows longevity – in fact, she wrote the book on it! But, through 100 Plus Capital, she is also now an investor in more than 15 longevity companies, and has no intention of slowing down. So what drives Arrison and what is she looking for in potential investments? We caught up with her recently to find out.

Arrison credits her interest in longevity in part to her grandfather, who lived healthily up until the ripe old age of 103.

“He had a great life, and he was a role model for all of us, and so that personally got me interested in longevity,” she says.

The path to longevity investment

But Arrison’s defining experience of longevity really came while working at US think-tank, the Pacific Research Institute, where she spent over a decade looking at the intersection of technology and public policy. Developments around nanotech and biotech in the early 2000s sparked her interest, which blossomed from there. She subsequently became an associate founder of Singularity University and published her book, 100 Plus, in 2011, which received positive reviews, including from Harvard Professor George Church.

It was while considering writing a second book on longevity that Arrison made her first investment in “fasting with food” company L-Nutra, after reading an article about founder Valter Longo’s philanthropic activities.

“My mission was to push the longevity movement forward, and it occurred to me after that first investment, that maybe the best way to do that was not writing another book, maybe I should do something else,” says Arrison. “I had the knowledge, I had the network, and I had some money. And so I thought ‘you know what, I’m going to become an investor’ – and that’s what I’m doing now.”

Key investments

Other investments followed quickly, and today Arrison is an investor in companies including Repair Biotechnologies, OncoSenX and Gordian Biotechnology. She focuses on pre-seed up to Series A investments, with check sizes typically ranging between $25,000 and $50,000.

“So I’m there at the very beginning of the company’s life, and I’m really enjoying it because I feel I have a lot of experience to share,” she says. “I’ve started my own company, I’ve run my own company, I’ve sold my own company, and I know a lot of people. I have no idea how to run a huge corporation, but I feel like I can really help companies in that phase where they’re just starting out.”

As someone investing in longevity, Arrison has her own views on what the term means when it comes to her investment focus.

“I’m investing in longevity broadly, so that includes the biotech companies, the regenerative medicine companies, the gene therapy companies, and I have invested in all of those,” she says. “But it also includes clean water, clean air – and even mental health, which is a really big part of longevity.”

Arrison highlights male contraceptive company Contraline as an example of one the companies in her portfolio that may not at first appear to have an obvious longevity angle.

“They have invented a first-of-its-kind, long lasting hydro gel, and that hydro gel has so many different biological purposes, which is why it’s also a longevity company,” she says, before mentioning her most recent investment, in exosome company Clara Biotech. “When I find companies like that, that have both a “now” and a “future” application, I love that.”

The longevity opportunity

So how does Arrison feel about the current state of the longevity market from an investor perspective?

“The real money is starting to really flow in, not just from firms that focus on longevity, but also from the big investment firms,” she says. “All of these traditional VCs who are now flocking to the space because there are real bets to be made that are really going to change the world.”

Image courtesy of Sonia Arrison

 

 

Comment on this article

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Nutriop

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Supplement report

Related articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Huma’s $130m raise will scale its digital health platform

With the goal of bringing proactive, predictive care to all, Huma has $130 million financing from leading health and technology companies. The investment arms of...

Pacific AM hires healthcare manager Dani Saurymper for new fund

Pacific Asset Management has hired Dani Saurymper from AXA IM – new fund lined up for the healthcare manager. Pacific Asset Management (PAM) has announced...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...
Supps report ad middle